The PennZone

WEXFORD, Pa., Oct. 24, 2024 ~ Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has recently announced an expansion of its license agreement with Deverra Therapeutics Inc. This move will allow Coeptis to broaden the potential applications of its allogeneic natural killer (NK) cell technology in the treatment of viral infections, pandemic-related illnesses, and emergency stockpiling for future health crises.

The agreement, which was initially secured in August 2023, granted Coeptis exclusive rights to key assets from Deverra including an allogeneic stem cell expansion and directed differentiation platform, two investigational new drug (IND) applications, and two Phase 1 clinical trial stage assets investigating DVX201 as an unmodified NK cell therapy generated from pooled donor CD34+ cells. These assets align with Coeptis' mission to develop treatments for targeting cancer, autoimmune and infectious diseases.

With this revised agreement, Coeptis will now have the ability to expand its field of use in the event of pandemic-related and emergency situations. This includes utilizing unmodified NK cells as a treatment for illnesses and injuries arising from a pandemic or act of terror or war, such as Acute Radiation Sickness (ARS). It also allows for the production and storage of unmodified NK cells in advance to prepare for future health crises.

More on The PennZone

• Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
• No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
• The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
• Sharon Pinkenson Chosen as Philly Girl Top 40 Winner
• Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies

Dave Mehalick, President and CEO of Coeptis Therapeutics expressed his excitement about this expansion stating that it "broadens the applicability of NK cells to ensure that we are prepared for future health crises and potentially address long term side effects that may arise as a result of a pandemic."

Coeptis Therapeutics Holdings, Inc., along with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Their goal is to disrupt conventional treatment paradigms and improve patient outcomes. The company's product portfolio includes assets licensed from Deverra Therapeutics, an allogeneic cellular immunotherapy platform, and DVX201, a clinical-stage unmodified natural killer cell therapy technology. They are also developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR) and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institutet.

More on The PennZone

• FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
• Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
• Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
• San Diego Attorney Anthony Z. Vargas Narrows Practice to Employment Law, Representing Employees Only
• Solid Earth Introduces RealtyID, a Universal Identity Spine for the Real Estate Industry

Coeptis' business model is centered around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements, co-development relationships, and strategic partnerships. Their focus is on expanding their product rights and offerings, particularly in the areas of cancer and infectious diseases. The company is headquartered in Wexford, PA.

It is important to note that this news release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations, forecasts, and assumptions that may cause actual results to differ materially from those projected. Coeptis urges readers to carefully review all cautionary statements regarding these forward-looking statements before making any investment decisions.

For more information on Coeptis Therapeutics Holdings, Inc., please visit their website at https://coeptistx.com/.

---

Show All News | Disclaimer | Report Violation